39.63

7.49% -3.21

Neurogene Inc (NGNE)

Overview News Price History Financials Discussions Forecast

Neurogene Inc stock is traded at $39.63, with a volume of 290.57K. It is down -7.49% in the last 24 hours and up +41.49% over the past month. Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Previous Close:

$42.84

Open:

$42.74

24h Volume:

290.57K

Relative Volume:

1.44

Market Cap:

$790.63M

Revenue:

$925.00K

Net Income/Loss:

$-98.64M

P/E Ratio:

-7.8958

EPS:

-5.0191

Net Cash Flow:

$-83.37M

1W Performance:

+12.14%

1M Performance:

+41.49%

6M Performance:

+121.15%

1Y Performance:

+80.46%

1-Day Range:

$38.18

$43.00

1-Week Range:

$32.00

$43.66

52-Week Range:

$15.93

$43.66

Neurogene Inc Stock (NGNE) Company Profile

Name

Neurogene Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

(877) 237-5020

Address

535 W 24TH STREET, NEW YORK

Employee

131

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

NGNE's Discussions on Twitter

Compare NGNE vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NGNE Neurogene Inc	39.63	790.63M	925.00K	-98.64M	-83.37M	-5.0191
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Neurogene Inc Stock (NGNE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Initiated	Craig Hallum	Buy
May-16-25	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-27-24	Initiated	BMO Capital Markets	Outperform
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-29-24	Initiated	Leerink Partners	Outperform
Mar-21-24	Initiated	William Blair	Outperform
Jan-08-24	Initiated	H.C. Wainwright	Buy
Jan-05-24	Initiated	Stifel	Buy
Jan-04-24	Initiated	TD Cowen	Outperform

View All

Neurogene Inc Stock (NGNE) Latest News

Jul 09, 2026

Neurogene Surges To A New 52-Week High: Will NGN-401 Reshape The Rett Syndrome Market? - RTTNews

Jul 09, 2026

Jul 08, 2026

Rett gene therapy drives lasting developmental gains: Long-term data - Rett Syndrome News

Jul 08, 2026

Neurogene (NGNE) CFO sells 4,800 shares and retains 84,040 including RSUs - Stock Titan

Jul 07, 2026

Neurogene president & CFO Cvijic sells $173,375 in stock By Investing.com - Investing.com Canada

Jul 07, 2026

A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $60 to $180 - Moomoo

Jul 07, 2026

Jul 06, 2026

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jul 06, 2026

Neurogene lures 6 new hires with stock options tied to July 6 close - Stock Titan

Jul 06, 2026

Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46 - Moomoo

Jul 06, 2026

Jul 04, 2026

Enterprise value to revenue forward of Neurogene Inc. – NASDAQ:NGNE - TradingView

Jul 04, 2026

Jul 03, 2026

Neurogene prices $125M equity offering - MSN

Jul 03, 2026

Neurogene announces pricing of $125 million public offering - The Pharma Letter

Jul 03, 2026

Jul 02, 2026

Neurogene president and CFO Cvijic sells $166,586 of company stock By Investing.com - Investing.com South Africa

Jul 02, 2026

Neurogene president and CFO Cvijic sells $166,586 of company stock - Investing.com

Jul 02, 2026

Form 4 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026

Neurogene (NGNE) CFO’s 4,800-share sale under 10b5-1 plan - Stock Titan

Jul 02, 2026

Neurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline Data - Seeking Alpha

Jul 02, 2026

Form 424B5 Neurogene Inc For: 2 July By Investing.com - Investing.com Canada

Jul 02, 2026

Neurogene Nets ~$135 Million From Equity Offering; Underwriters Exercise Full Option - TradingView

Jul 02, 2026

Neurogene (NGNE) secures $134.8M, extending cash runway into 2029 - Stock Titan

Jul 02, 2026

Citizens reiterates Taysha Gene Therapies stock rating on therapy progress By Investing.com - Investing.com Canada

Jul 02, 2026

Citizens reiterates Taysha Gene Therapies stock rating on therapy progress - Investing.com

Jul 02, 2026

Jul 01, 2026

Leerink raises Neurogene stock price target to $77 on Rett data By Investing.com - Investing.com South Africa

Jul 01, 2026

Neurogene (NGNE) sells 3.5M shares, pre-funded warrants in $117M deal - Stock Titan

Jul 01, 2026

Leerink raises Neurogene stock price target to $77 on Rett data - Investing.com Nigeria

Jul 01, 2026

Neurogene Inc. Stock 12‑Month Price Target Raised to $79.62, Implies 153% Upside - TradingView

Jul 01, 2026

Neurogene prices $125 million public offering at $30 per share By Investing.com - Investing.com Australia

Jul 01, 2026

Neurogene prices $125 million public offering at $30 per share - Investing.com

Jul 01, 2026

Neurogene Sets Pricing For $125 Million Public Offering - TradingView

Jul 01, 2026

Why is Neurogene stock sliding today? By Investing.com - Investing.com Canada

Jul 01, 2026

Neurogene Prices $125 Million Public Offering - marketscreener.com

Jul 01, 2026

Neurogene locks in $125M stock sale, closing expected July 2 - Stock Titan

Jul 01, 2026